natgillin/translations-raw huggingface dataset:
Olazax, 5 mg, 7.5 mg, 10 mg, 15 mg, 20 mg are available in aluminium foil blisters of 28 tablets
Olazax 5 mg, 7,5 mg, 10 mg, 15 mg, 20 mg je dostupan u blisterima od aluminijske folije s 28 tableta.
Old age and low body mass index are known risk factors for common adverse reactions of pharmacological doses of glucocorticoids such as osteoporosis, thinning of skin, diabetes mellitus, hypertension and increased susceptibility to infections.
Starost i nizak indeks tjelesne mase poznati su čimbenici rizika za česte neželjene reakcije na farmakološke doze glukokortikoida, kao što su osteoporoza, stanjivanje kože, dijabetes melitus, hipertenzija i povećana osjetljivost na infekcije.
Older (>60 years)
Starije osobe (>60 godina)
Older adults may be more sensitive to the effects of this medicine
Starije osobe mogu biti osjetljivije na djelovanje ovog lijeka
Older children (12-16 years) had mean clearance values similar to those determined in adult patients.
Starija djeca (12–16 godina) imala su srednje vrijednosti klirensa slične onima koje su bile utvrđene u odraslih bolesnika.
Older children (6 <12 years)
Starija djeca (6 < 12 godina)
Older children (6 <12 years)
Starija djeca (6 <12 godina)
Older children (6<12 years)
Starija djeca (6 – <12 godina)
Older children and adults on a prophylaxis regimen used an average dose of 27 IU/kg and experienced an average of 10 bleeding episodes per year.
Starija djeca i odrasli na profilaktičkom režimu uzimali su prosječnu dozu od 27 IU/kg i imali u prosjeku 10 epizoda krvarenja godišnje.
Older men
Stariji muškarci
Older men (≥ 65 years old)
Stariji muškarci (≥ 65 godina)
Older patients (aged 65 years and over)
Stariji bolesnici (u dobi od 65 godina i stariji)
Older patients (≥ 75 years of age; n = 321) had a similar adverse reaction profile compared to younger patients (< 65 years of age; n = 1,016), but had a higher incidence of hypotension (2% versus < 1%).
Stariji bolesnici (≥ 75 godina starosti; n = 321) imali su sličan profil nuspojava u usporedbi s mlađim bolesnicima (< 65 godina starosti; n = 1016), ali su imali veću incidenciju hipotenzije (2% odnosno < 1%).
Older patients experienced more Grade 3 or higher adverse reactions compared to younger patients (32% versus 28%).
Stariji bolesnici imali su više nuspojava stupnja 3 ili višeg, u usporedbi s mlađim bolesnicima (32% naspram 28%).
Older patients who cannot swallow capsules may also receive the appropriate dose of the oral suspension.
Stariji bolesnici koji ne mogu progutati kapsule mogu također primiti odgovarajuću dozu oralne suspenzije.
Older people
Starija populacija
Older people
Starije bolesnici
Older people
Stariji bolesnici
Older people
Stariji ljudi
Older people
Stariji ljudi.
Older people  65 years)
Stariji osobei (≥ 65 godina)
Older people (age 65 years and over)
Starije osobe (65 godina i starije)
Older people (age 65 years and over)
Starije osobe (65 godina starosti i više)
Older people (age above 65 years)
Starije osobe (iznad 65 godina starosti)
Older people (over 65 years of age)
Starije osobe (iznad 65 godina života)
Older people (over 65 years of age)
Stariji bolesnici (iznad 65 godina života)
Older people (≥ 65 years of age): Specific pharmacokinetic evaluations for elderly subjects have not been performed.
Starije osobe (≥ 65 godina): nisu provedena posebna ispitivanja farmakokinetike ribavirina za starije bolesnike.
Older people (≥ 65 years of age): Specific pharmacokinetic evaluations for elderly subjects have not been performed.
Stariji osobe (≥ 65 godina): nisu provedena posebna ispitivanja farmakokinetike ribavirina za starije bolesnike.
Older people (≥ 65 years old)
Starije osobe (≥ 65 godina)
Older people (≥ 65 years)
Starije osobe (≥ 65 godina)
Older people (≥ 65 years) and race
Starije osobe (≥ 65 godina) i rasa
Older people (≥ 65 years): No dose adjustment is required (see sections 4.4 and 5.2).
Starije osobe (≥ 65 godina): Nije potrebno prilagođavati dozu (vidjeti dijelove 4.4 i 5.2).
Older people (≥65 years of age) may be more likely to experience adverse reactions.
U starijih osoba (≥ 65 godina) može postojati veća vjerojatnost nuspojava.
Older people (≥65 years)
Starije osobe (≥ 65 godina)
Older people (≥65 years)
Starije osobe (≥65 godina)
Older people ( 75 years)
Starije osobe ( 75 godina)
Older people and patients with chronic cardiac and/or respiratory disease
Starije osobe i bolesnici s kroničnim srčanim bolestima i/ili bolestima dišnog sustava
Older people and patients with chronic cardiac and/or respiratory disease
Stariji bolesnici i bolesnici s kroničnim srčanim bolestima i/ili bolestima dišnog sustava
Older people and patients with chronic cardiac and/or respiratory disease
Stariji osobe i bolesnici s kroničnim srčanim bolestima i/ili bolestima dišnog sustava
Older people have been shown to have increased systemic exposure to icatibant.
Pokazalo se da je kod starijih osoba povećana sistemska izloženost ikatibantu.
Older people patients treated with TCF should be closely monitored.
Starije osobe liječene sa TCF trebaju biti pod stalnim nadzorom.
Older people patients ≥65 years had an increased risk of diarrhoea, dizziness, asthenia, weight loss and dehydration.
U starijih osoba u dobi od ≥ 65 godina postoji povećan rizik od proljeva, omaglice, astenije, gubitka tjelesne težine i dehidracije.
Older people should be closely monitored for the development of diarrhoea and potential dehydration (see section 4.4).
Starije osobe treba pažljivo motriti zbog razvoja proljeva i moguće dehidracije (vidjeti dio 4.4).
Older people, gender, and race
Starije osobe, spol i rasa
Older people: although consideration should be given to initiating therapy with 75 mg in patients over 75 years of age, dosage adjustment is not usually necessary for older people.
Starije osobe: iako za bolesnike starije od 75 godina treba razmotriti započinjanje terapije dozom od 75 mg, dozu obično nije potrebno prilagoditi u starijih osoba.
Older people: although consideration should be given to initiating therapy with 75 mg in patients over 75 years of age, dosage adjustment is not usually necessary for theolder people.
Starije osobe: iako za bolesnike starije od 75 godina treba razmotriti započinjanje terapije dozom od 75 mg, dozu obično nije potrebno prilagoditi u starijih osoba.
Older people: although consideration should be given to initiating therapy with 75 mg in patients over 75 years of age, dosage adjustment is not usually necessary forolder people.
Starije osobe: iako za bolesnike starije od 75 godina treba razmotriti započinjanje terapije dozom od 75 mg, dozu obično nije potrebno prilagoditi u starijih osoba.
Older people: Imatinib pharmacokinetics has not been specifically studied in the older people.
Starije osobe: farmakokinetika imatiniba nije specifično ispitivana u starijih osoba.
Older people: Imatinib pharmacokinetics have not been specifically studied in older people.
Stariji ljudi:farmakokinetika imatiniba nije specifično ispitivana u starijih ljudi.
Older people: no dosage adjustment of CoAprovel is necessary in older people.
Starije osobe: nije potrebno prilagođavati dozu lijeka CoAprovel za starije osobe.
Older people: no dosage adjustment of CoAprovel is necessary inolder people.
Starije osobe: nije potrebno prilagođavati dozu lijeka CoAprovel za starije osobe.
Older people: no dosage adjustment of Irbesartan Hydrochlorothiazide Zentiva is necessary in older people.
Starije osobe: nije potrebno prilagođavati dozu lijeka Irbesartan Hydrochlorothiazide Zentiva za starije osobe.
Older people: no dosage adjustment of Irbesartan Hydrochlorothiazide Zentiva is necessary inolder people.
Starije osobe: nije potrebno prilagođavati dozu lijeka Irbesartan Hydrochlorothiazide Zentiva za starije osobe.
Older people: no dosage adjustment of Karvezide is necessary in older people.
Starije osobe: nije potrebno prilagođavati dozu lijeka Karvezide za starije osobe.
Older people: No dose adjustment of Corbilta is required for older people.
Starije osobe: starijim osobama nije potrebno prilagođavati dozu Corbilte.
Older people: No dose adjustment of Levodopa/Carbidopa/Entacapone Orion is required for older people.
Starije osobe: starijim osobama nije potrebno prilagođavati dozu Levodopa/Carbidopa/Entacapone Oriona.
Older people: No dose adjustment of Stalevo is required for older people.
Starije osobe: starijim osobama nije potrebno prilagođavati dozu Staleva.
Older people: On the basis of the clinical studies, the recommended dose for patients over the age of 65 years is 20 mg per day (2 ml solution, equivalent to four pump actuations) as described above.
Starije osobe: temeljem kliničkih ispitivanja, preporučena doza za bolesnike starije od 65 godina iznosi 20 mg na dan (2 ml otopine što odgovara četiri potiska pumpice), kao što je gore opisano.
Older people: On the basis of the clinical studies, the recommended dose for patients over the age of 65 years is 20 mg per day (20 mg once a day) as described above.
Starije osobe: temeljem kliničkih ispitivanja preporučena doza za bolesnike starije od 65 godina iznosi 20 mg na dan (20 mg jednom dnevno), kao što je gore opisano.
Older people: On the basis of the clinical studies, the recommended dose for patients over the age of 65 years is 20 mg per day (two 10 mg tablets once a day) as described above.
Starije osobe: temeljem kliničkih ispitivanja preporučena doza za bolesnike starije od 65 godina iznosi 20 mg dnevno (dvije filmom obložene tablete od 10 mg jednom dnevno), kao što je gore opisano.
Older people: On the basis of the clinical studies, the recommended dose for patients over the age of 65 years is 20 mg per day as described above.
Starije osobe: temeljem kliničkih ispitivanja preporučena doza za bolesnike starije od 65 godina iznosi 20 mg na dan, kao što je gore opisano.
Older people: There is limited clinical data on the use of TRISENOX in the elderly population.
Starije osobe: Dostupni su ograničeni podaci o primjeni TRISENOXA u starije populacije.
Older people: When given without carbidopa and entacapone, the absorption of levodopa is greater and elimination is slower in older people than in young people.
Starije osobe: kada se daje bez karbidope i entakapona, apsorpcija levodope je veća i izlučivanje polaganije u starijih nego u mlađih osoba.
Older peoples
Starije osobe
Older poeple: On the basis of the clinical studies, the recommended dose for patients over the age of 65 years is 20 mg per day (two 10 mg tablets once a day) as described above.
Starije osobe: temeljem kliničkih ispitivanja preporučena doza za bolesnike starije od 65 godina iznosi 20 mg dnevno (dvije filmom obložene tablete od 10 mg jednom dnevno), kao što je gore opisano.
OLE week 12
OLE 12. tjedan
OLE week 12 (n = 16)
OLE 12. tjedan (n = 16)
OLE week 24
OLE 24. tjedan
OLE week 24 (n = 8)
OLE 24. tjedan (n = 8)
OLE week 36
OLE 36. tjedan
OLE week 36 (n = 5)
OLE 36. tjedan (n = 5)
Oleic acid
oleatna kiselina
olid organ cancers
zloćudni tumori solidnih organa
olid organ neoplasm (including breast cancer,
novotvorine na solidnim organima (uključujući rak
Oligohydramnios
oligohidramnion
Oligomenorrhoea
oligomenoreja
Oligospermia , azoospermia4
oligospermija, azoospermija4
Oligospermia,azoospermia4
oligospermija, azoospermija4
OLM-M = olmesartan medoxomil, LS = least squares, LOCF = last observation carried forward
OLM-M = olmesartan medoksomil, LS = najmanji kvadrati, LOCF = prijenos zadnje mjerene vrijednosti
OLM-M = olmesartan medoxomil, LS = least squares, LOCF = last observation carried forward
OLM-M = olmesartanmedoksomil, LS = najmanji kvadrati, LOCF = prijenos zadnje mjerene vrijednosti
Olopatadine in the form of eye drops (OPATANOL) has not been studied in patients with renal or hepatic disease.
Primjena olopatadina u obliku kapi za oko (OPATANOL) nije proučena u bolesnika s bolestima bubrega ili jetre.
Olopatadine is not recommended during pregnancy and in women of childbearing potential not using contraception.
Primjena OPATANOLA se ne preporučuje tijekom trudnoće niti u žena reproduktivne dobi koje ne koriste kontracepciju.
Olopatadine.
Olopatadin.
olsalazine or mesalazine (used for a bowel disorder called ulcerative colitis)
olsalazin ili melsalazin (lijekovi za bolest crijeva koju nazivamo ulcerozni kolitis)
olution for infusion
infuziju
olution for infusion solution for infusion
EU/1/11/698/002
olvent 4 ml (125 IU/ml)
otapalo 4 ml (125 IU/ml)
olvent 4 ml (250 IU/ml)
otapalo 4 ml
olvent 4 ml (250 IU/ml)
otapalo 4 ml (250 IU/ml)
olvent 4 ml (500 IU/ml)
otapalo 4 ml
olvent 4 ml (500 IU/ml)
otapalo 4 ml (500 IU/ml)
olvent 4 ml (62.5 IU/ml)
otapalo 4 ml
olvent 4 ml (62.5 IU/ml)
otapalo 4 ml (62,5 IU/ml)
olvent 4 ml (750 IU/ml)
otapalo 4 ml (750 IU/ml)
olvent: 10 ml
otapalo: 10 ml
olvent: 2.5 ml
otapalo: 2,5 ml
olvent: 2.5 ml (100 IU/ml)
EU/1/00/143/008
olvent: 2.5 ml (100 IU/ml)
otapalo: 2,5 ml (100 IU/ml)
olvent: 2.5 ml (200 IU/ml)
otapalo: 2,5 ml (200 IU/ml)
olvent: 2.5 ml (400 IU/ml)
otapalo: 2,5 ml (400 IU/ml)
olvent: 3 ml
otapalo: 3 ml
olvent: 5 ml
otapalo: 5 ml
olvent: 5 ml (150 mg/ml)
otapalo: 5 ml (150 mg/ml)
olvent: 5 ml (400 IU/ml)
otapalo: 5,0 ml (400 IU/ml)
olvent: 5 ml (600 IU/ml)
otapalo: 5,0 ml (600 IU/ml)
Olysio can only be obtained with a prescription and treatment should be started and monitored by a doctor experienced in the management of patients with chronic hepatitis C.
Olysio se izdaje samo na liječnički recept, a liječenje mora započeti i nadzirati liječnik iskusan u liječenju bolesnika oboljelih od kroničnog hepatitisa C.
OLYSIO contains the active substance ‘simeprevir’.
OLYSIO sadrži djelatnu tvar “simeprevir“.
OLYSIO in combination with peginterferon alfa and ribavirin
OLYSIO u kombinaciji s peginterferonom alfa i ribavirinom
OLYSIO in combination with peginterferon alfa and ribavrin
OLYSIO u kombinaciji s peginterferonom alfa i ribavrinom
OLYSIO in combination with peginterferon alfa-2b
OLYSIO u kombinaciji s peginterferonom alfa-2b
OLYSIO in combination with sofosbuvir
OLYSIO u kombinaciji sa sofosbuvirom
Olysio is available as 150 mg capsules.
Olysio je dostupan u kapsulama od 150 mg.
Olysio is used in combination with other medicines.
Olysio se koristi u kombinaciji s drugim lijekovima.
OLYSIO is used with other medicines to treat chronic (long-term) hepatitis C infection in adults.
OLYSIO se koristi s drugim lijekovima za liječenje kronične (dugotrajne) infekcije hepatitisom C u odraslih.
Olysio must be used in combination with other medicines used to treat chronic hepatitis C, such as with peginterferon alfa and ribavirin or with sofosbuvir.
Olysio se mora koristiti u kombinaciji s drugim lijekovima za liječenje kroničnog hepatitisa C, primjerice s peginterferonom alfa i ribavirinom ili sa sofosbuvirom.
OLYSIO must not be used by itself.
OLYSIO se ne smije uzimati samostalno.
OLYSIO should only be co-administered with other direct acting antiviral medicinal products if the benefits are considered to outweigh the risks based upon available data.
OLYSIO se smije primijeniti istodobno s ostalim antivirusnim lijekovima direktnog učinka samo ako se na temelju dostupnih podataka procijeni da korist nadvladava rizik.
Olysio taken together with sofosbuvir was investigated in a study involving 167 patients, which showed that the combination (with or without ribavirin) cleared infection with hepatitis C genotype 1 in around 90% of patients 12 weeks after the end of treatment.
Primjena lijeka Olysio zajedno sa sofosbuvirom ispitana je u grupi od 167 bolesnika, a rezultati su pokazali da je ova kombinacija (s ribavirinom ili bez njega) 12 tjedana nakon završetka liječenja izliječila infekciju hepatitisom C genotipa 1 u više od 90 % bolesnika.
Omalizumab crosses the placental barrier and the potential for harm to the foetus is unknown.
Omalizumab prelazi placentnu barijeru, dok potencijalna škodljivost na fetus nije poznata.
Omalizumab is a humanised monoclonal antibody manufactured by recombinant DNA technology in a Chinese hamster ovary (CHO) mammalian cell line.
Omalizumab je humanizirano monoklonsko protutijelo proizvedeno tehnologijom rekombinantne DNK iz stanične linije jajnika sisavca kineskog hrčka (CHO).
Omalizumab should not be given during breast-feeding.
Omalizumab se ne smije primjenjivati tijekom dojenja.
Omalizumab studies 1 and 3 Pooled
i 3. ispitivanje omalizumaba objedinjeno
Omalizumab studies 1, 2 and 3 Pooled
1., 2. i 3. ispitivanje omalizumaba objedinjeno
omatostatin analogues (such as octreotide, used to treat an uncommon condition in which you make too much growth hormone),
analoge somatostatina (poput oktreotida, koji se koristi za liječenje manje čestog poremećaja kod kojega osoba proizvodi previše hormona rasta)
omatostatin analogues (such as octreotide, used to treat an uncommon condition in which you make too much growth hormone), sulphonamide antibiotics.
analoge somatostatina (poput oktreotida, koji se koristi za liječenje manje česte bolesti kod koje organizam proizvodi previše hormona rasta) sulfonamidne antibiotike
omatropin (growth hormone),
omatropin (hormon rasta)
omatropin (growth hormone),
omatropin (hormon rasta) ,
omatropin (growth hormone),
omatropin (hormon rasta),
ombitasvi
(13,0-21,2)
ombitasvi
0,81
ombitasvi
ombitasvir/p
ombitasvi
tonavir
ombitasvi r/paritapr
ombitasvir/p
ombitasvir
0,82
ombitasvir
0,93
ombitasvir
0,96
ombitasvir
1,02
ombitasvir
1,07
ombitasvir
1,22
ombitasvir
1,46
ombitasvir
2,07
ombitasvir
jedanput na
ombitasvir
karisoprodol; primijeniti
ombitasvir
paritaprevir
ombitasvir
uzrokuju
Ombitasvir + Paritaprevir + Ritonavir with RBV
Ombitasvir + paritaprevir + ritonavir s RBV
Ombitasvir + paritaprevir + ritonavir* for 12 weeks
Ombitasvir + paritaprevir + ritonavir* tijekom 12 tjedana
Ombitasvir has EC50 values of 12, 4.3, 19, 1.7, 3.2, and 366 pM against replicon cell lines constructed with NS5A from single isolates representing genotypes 2a, 2b, 3a, 4a, 5a, and 6a, respectively.
Vrijednosti EC50 ombitasvira protiv staničnih linija replikona konstruiranih s NS5A iz pojedinačnih izolata koji su predstavljali genotipove 2a, 2b, 3a, 4a, 5a odnosno 6a iznosile su 12; 4,3; 19; 1,7; 3,2 odnosno
ombitasvir paritaprevir
ili rosuvastatina.
Ombitasvir was not carcinogenic in a 6-month transgenic mouse study up to the highest dosage tested (150 mg/kg/day), resulting in ombitasvir AUC exposures approximately 26-fold higher than those in humans at the recommended clinical dose of 25 mg.
U 6-mjesečnom istraživanju na transgeničnim miševima, ombitasvir nije bio kancerogen ni pri najvišoj ispitivanoj dozi (150 mg/kg/dan), koja je dovela do približno 26 puta veće izloženosti ombitasviru (određene na temelju AUC-a) od izloženosti koja se postiže u ljudi nakon primjene preporučene kliničke doze od 25 mg.
Ombitasvir, paritaprevir, and ritonavir do not inhibit organic anion transporter (OAT1) in vivo as shown by the lack of interaction with tenofovir (OAT1 substrate).
Ombitasvir, paritaprevir i ritonavir ne inhibiraju prijenosnik organskih aniona (OAT1) in vivo što je dokazano nepostojanjem interakcije s tenofovirom (supstrat prijenosnika OAT1).
ombitasvir/ paritaprevi r/ritonavir
aritaprevir/ri
ombitasvir/ paritaprevi r/ritonavir
ombitasvir/p
ombitasvir/ paritaprevir
(0,88-0,99)
ombitasvir/ paritaprevir
ombitasvir/paritaprevir/
ombitasvir/ paritaprevir
Sulfametoks azol,
ombitasvir/paritaprevir/rito
1,15 (1,08-1,23)
ombitasvir/paritaprevir/rito
CYP3A/eflu
Ombitasvir: AUC: ↑1.3-fold Cmax: ↔
Ombitasvir: AUC: ↑ 1,3 puta Cmax: ↔
ome antibiotics (for example ciprofloxacin, enoxacin) certain antidepressants such as fluvoxamine.
neke antibiotike (primjerice ciprofloksacin, enoksacin) određene antidepresive kao što je fluvoksamin.
ome antibiotics, such as clarithromycin, doxycyline and telithromycin some medicines for tuberculosis (TB), such as rifampicin
neke antibiotike, poput klaritromicina, doksiciklina i telitromicina neke lijekove protiv tuberkuloze (TBC), poput rifampicina
ome antidepressants (monoamine oxidase inhibitors or selective serotonin reuptake inhibitors),
neke antidepresive (inhibitore monoamino-oksidaze ili selektivne inhibitore ponovne pohrane serotonina),
ome antidepressants (monoamine oxidase inhibitors or selective serotonin reuptake inhibitors),
neke antidepresive (inhibitore monoaminooksidaze ili selektivne inhibitore ponovne pohrane serotonina),
ome antifungal agents (used to treat fungal infections) such as ketoconazole, itraconazole, certain antibiotics, may extend the effects of this medicine. some medicines may decrease the effect of Suboxone.
neki antifungalni lijekovi (koriste se za liječenje gljivica) poput ketokonazola, itrakonazola i određenih antibiotika mogu produljiti učinke ovog lijeka. neki lijekovi mogu smanjiti učinke lijeka Suboxone.
ome antifungal agents (used to treat fungal infections) such as ketoconzaole, itraconazole, certain antibiotics may extend the effects of this medicine. some medicines may decrease the effect of Suboxone.
neki antifungalni lijekovi (koriste se za liječenje gljivica) poput ketokonazola, itrakonazola i određenih antibiotika mogu produljiti učinke ovog lijeka. neki lijekovi mogu smanjiti učinke lijeka Suboxone.
ome antifungals such as ketaconazole
neke antimikotike kao što je ketokonazol
ome antipsychotics (e.g. thioridazine, chlorpromazine, levomepromazine, trifluoperazine, cyamemazine, sulpiride, sultopride, amisulpride, tiapride, pimozide, haloperidol, droperidol) others (e.g. bepridil, cisapride, diphemanil, erythromycin IV, halofantrin, mizolastin, pentamidine, sparfloxacine, terfenadine, vincamine IV)
neki antipsihotici (npr. tioridazin, klorpromazin, levomepromazin, trifluoperazin, cijamemazin, sulpirid, sultoprid, amisulprid, tijaprid, pimozid, haloperidol, droperidol) ostali (npr. bepridil, cisaprid, difemanil, eritromicin i.v., halofantrin, mizolastin, pentamidin, sparfloksacin, terfenadin, vinkamin i.v.)
ome antipsychotics (e.g. thioridazine, chlorpromazine, levomepromazine, trifluoperazine, cyamemazine, sulpiride, sultopride, amisulpride, tiapride, pimozide, haloperidol, droperidol) others (e.g. bepridil, cisapride, diphemanil, erythromycin IV, halofantrin, mizolastin, pentamidine, sparfloxacine, terfenadine, vincamine IV.)
neki antipsihotici (npr. tioridazin, klorpromazin, levomepromazin, trifluoperazin, cijamemazin, sulpirid, sultoprid, amisulprid, tijaprid, pimozid, haloperidol, droperidol) ostali (npr. bepridil, cisaprid, difemanil, eritromicin i.v., halofantrin, mizolastin, pentamidin, sparfloksacin, terfenadin, vinkamin i.v.)
ome antipsychotics (e.g. thioridazine, chlorpromazine, levomepromazine, trifluoperazine, cyamemazine, sulpiride, sultopride, amisulpride, tiapride, pimozide, haloperidol, droperidol) others (e.g. bepridil, cisapride, diphemanil, erythromycin IV, halofantrin, mizolastin, pentamidine, sparfloxacine, terfenadine, vincamine IV.)
neki antipsihotici (npr. tioridazin, klorpromazin, levomepromazin, trifluoperazin, cijamemazin, sulpirid, sultoprid, amisulprid, tijaprid, pimozid, haloperidol, droperidol) ostali: (npr. bepridil, cisaprid, difemanil, eritromicin i.v., halofantrin, mizolastin, pentamidin, sparfloksacin, terfenadin, vinkamin i.v.)
ome blood parameters increased (blood alkaline phosphatase increased) prolonged coagulation (clotting) test times
povišeni neki krvni parametri (povišena alkalna fosfataza u krvi) produženo vrijeme u testovima koagulacije (zgrušavanja krvi)
ome calcium channel blockers, used to treat high blood pressure, such as diltiazem, felodipine, nicardipine, nifedipine or verapamil
neke blokatore kalcijevih kanala koji se koriste za liječenje visokog krvnog tlaka, poput diltiazema, felodipina, nikardipina, nifedipina ili verapamila
ome chemotherapy medicines - such as docetaxel or etoposide
neke kemoterapijske lijekove - kao što su docetaksel ili etopozid
ome immunosuppressants, such as cyclosporin, tacrolimus and sirolimus
neke imunosupresive, poput ciklosporina, takrolimusa i sirolimusa
ome laxatives
neke laksative
ome medicines affecting the immune system - such as ciclosporin, sirolimus (rapamycin), tacrolimus
neke lijekove koji djeluju na imunološki sustav, poput ciklosporina, sirolimusa (rapamicina), takrolimusa
ome medicines against blood clot formation such as warfarin,
neke lijekove protiv stvaranja krvnih ugrušaka, kao što je varfarin,
ome medicines for depression called tricyclic antidepressants,
neke lijekove za liječenje depresije koji se zovu triciklički antidepresivi,